Top View
- California Health & Wellness
- PF-00299804 Bosutinib Axitinib
- Avelumab 20Mg/Ml Concentrate for Solution for Infusion (Bavencio®) Merck Kgaa/Pfizer
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- FDA Updates Highlighting the Latest Cancer Treatments
- Open Full Page
- Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance- Pharmacodynamic Study
- Maximizing Clinical Outcomes with Axitinib Therapy in Advanced Renal Cell Carcinoma Through Proactive Side-Effect Management
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- ATC/DDD Classification (Final)
- INLYTA (Axitinib) Is a Kinase Inhibitor
- “I Fight.” “I Was in the Waiting Room
- Inlyta, Through the Centralised Procedure Falling Within the Article 3(1) and Point 3 of Annex of Regulation (EC) No 726/2004
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Avelumab-Axitinib
- Axitinib for the Treatment of Patients with Advanced Metastatic Renal Cell Carcinoma (Mrcc) After Failure of Prior Systemic Treatment
- Renal Cell Carcinoma Treatment Regimens
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Axitinib As First-Line Therapy in Metastatic Renal Cell Carcinoma
- Targeting Tyrosine Kinases in Renal Cell Carcinoma: “New Bullets Against Old Guys”
- Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
- INLYTA® (Axitinib) Tablets Fact Sheet
- Axitinib Plus Immune Checkpoint Inhibitor: Evidence- and Expert-Based Consensus Recommendation for Treatment Optimisation and Management of Related Adverse Events
- Colorectal Cancer Growth Retardation Through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
- Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk
- Axitinib and Sorafenib in Second-Line Treatment of Advanced Renal Cell Carcinoma
- Oncology Therapy for the Generalist
- Full-Year 2020 Results Clinical Trials Appendix PDF 2537KB
- Focus on Metastatic Renal Cell Carcinoma
- Molecular Conformations, Interactions, and Properties Associated with Drug
- Efficacy of Axitinib As Second-Line Treatment in Locally Advanced And
- Axitinib for the Treatment of Metastatic Renal Cell Carcinoma Recommendations for Therapy Management to Optimize Outcomes
- BC Cancer Protocol Summary for the Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and Axitinib
- Targeted Therapies for Previously Treated Advanced Or Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis
- Comparison of Efficacy and Safety Among Axitinib, Sunitinib, And
- Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors (Review)
- Combination Strategy Targeting VEGF and HGF/C-Met in Human Renal Cell Carcinoma Models
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Hypoxic 3D in Vitro Culture Models Reveal Distinct Resistance Processes to Tkis in Renal Cancer Cells Zofa F
- NICE Technology Appraisals About Medicines: Formulary Adherence
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib
- Axitinib (Inlyta®) EOCCO POLICY
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Renal Cell Carcinoma After Failure of Prior Systematic Treatment
- Pancreatitis Associated with Newer Classes of Antineoplastic Therapies
- A Streamlined Search Technology for Identification of Synergistic Drug
- 202324Orig1s000
- INLYTA (Axitinib) Is a Kinase Inhibitor
- Pharmacological Research the Role of Small Molecule Kit Protein-Tyrosine
- Pharmacogenetics-Based Area-Under-Curve Model Can Predict Efficacy and Adverse Events from Axitinib in Individual Patients with Advanced Renal Cell Carcinoma
- Alternating Or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated Or Blastic Phases 2015-0787
- Axitinib and Crizotinib Combination Therapy Inhibits Bone Loss in A
- Thyroid Effects of Tyrosine Kinase Inhibitors
- Evaluation of Drug Therapy Costs for Patients with Breast Cancer, Melanoma and Renal Cell Carcinoma in Moscow in 2016-2017
- Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment with Tyrosine Kinase Inhibitors